GlassScriptPhysician profile
Anthony R Aventa
NPI 1801875034
$4,651.05
in general payments reported to CMS, 2019-2025
27 companies · $1,354 in 2025
The $1,354 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $36.11 · 2021: $74.39 · 2022: $539 · 2023: $1,165 · 2024: $1,259 · 2025: $1,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,777.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,137.17 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,042.54 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $613.63 | 2019-2025 | Mounjaro, Kisunla, Zepbound |
| Abbott Laboratories | $516.48 | 2022-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.19 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $143.68 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $115.95 | 2023-2025 | |
| Eisai INC. | $109.53 | 2025 | |
| Abbvie INC. | $100.86 | 2019-2024 | Vraylar |
| Idorsia Pharmaceuticals US INC | $72.49 | 2022-2024 | Quviviq |
| Gilead Sciences, INC. | $54.07 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $53.52 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $47.28 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $45.16 | 2019 | |
| Atricure, INC. | $44.55 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $40.65 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astrazeneca Pharmaceuticals LP | $33.75 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $30.55 | 2021-2025 | |
| Daiichi Sankyo INC. | $29.50 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $28.94 | 2022 | |
| Sumitomo Pharma America, INC. | $28.55 | 2024 | Gemtesa |
| Beta Bionics, INC. | $25.62 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Alvogen INC | $23.60 | 2024 | Teriparatide |
| Axsome Therapeutics, INC. | $21.88 | 2025 | Auvelity |
| Si-Bone, INC. | $19.67 | 2019 | |
| Corium, LLC | $16.33 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Aventa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.